FENC Fennec Pharmaceuticals Inc.

6.18
+0.06  (+1%)
Previous Close 6.12
Open 6.01
Price To Book 7.98
Market Cap 122,956,229
Shares 19,895,830
Volume 44,796
Short Ratio
Av. Daily Volume 38,793
Stock charts supplied by TradingView

NewsSee all news

  1. Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results

    NDA (New Drug Application) for PEDMARKTM to be completed in early 2020Strong financial position with $15.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fennec

  2. Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

    RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of

  3. Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of

  4. Fennec Appoints Shubh Goel as Chief Commercial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling NDA to be completed early 2020.
Pedmark (sodium thiosulfate)
Cisplatin-induced ototoxicity

Latest News

  1. Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results

    NDA (New Drug Application) for PEDMARKTM to be completed in early 2020Strong financial position with $15.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fennec

  2. Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

    RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of

  3. Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of

  4. Fennec Appoints Shubh Goel as Chief Commercial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of